Full-Time
Develops continuous glucose monitoring systems
No salary listed
Senior, Expert
Company Does Not Provide H1B Sponsorship
Minna, Inverin, Co. Galway, Ireland
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides real-time glucose readings, enabling users to monitor their blood sugar levels effectively. This system includes a sensor that is placed under the skin, which continuously measures glucose levels and sends the data to a smartphone or display device. Unlike traditional glucose monitoring methods that require finger pricks, Dexcom's technology offers a more convenient and less invasive way to track glucose levels. The company differentiates itself from competitors by focusing on user-friendly devices and comprehensive data analytics through its software application, Dexcom CLARITY, which helps users and healthcare providers make informed decisions based on glucose trends. The goal of Dexcom is to enhance the quality of life for people with diabetes by providing accurate and accessible glucose monitoring solutions.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1999
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Professional Development Budget
Remote Work Options
Flexible Work Hours
Tuition Reimbursement
In March, cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.
What You Should Know:– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.– The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.Dexcom G7 FeaturesThe Dexcom G7 15 Day system offers up to 15.5 days of wear allowing users to benefit from fewer monthly sensors and reduced monthly waste. The waterproof CGM system provides an overall MARD of 8.0%.Other key features of Dexcom G7 include:Apple Watch Connectivity: Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone.Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone. Automated Logging: Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels.Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels. 12-Hour Grace Period: A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions.A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions. Mobile App with Dexcom Clarity: An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports.An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports
Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference.
Dexcom names Masimo exec Jon Coleman as CCO.
Dexcom opening date hiring 1000 jobs as highly skilled workers wanted.